Currently out of the existing stock ratings of Bryan Brokmeier, 30 are a BUY (93.75%), 2 are a HOLD (6.25%).

Bryan Brokmeier

Work Performance Price Targets & Ratings Chart

Analyst Bryan Brokmeier, carries an average stock price target met ratio of 81.48% that have a potential upside of 68.06% achieved within 526 days. Previously, Bryan Brokmeier worked at CANTOR FITZGERALD.

Bryan Brokmeier’s has documented 55 price targets and ratings displayed on 10 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on TTOO, T2 Biosystms at 03-May-2017.

Wall Street Analyst Bryan Brokmeier

Analyst best performing recommendations are on PACB (PACIFIC BIOSCIENCES OF CALIFORNIA).
The best stock recommendation documented was for TTOO (T2 BIOSYSTMS) at 5/3/2017. The price target of $30000 was fulfilled within 133 days with a profit of $10150 (51.13%) receiving and performance score of 3.84.

Average potential price target upside

of $28.4 (21.67%) on WAT (WATERS).
of $11.93 (26.83%) on PKI (PERKINELMER).
of $6.99 (119.55%) on VCYT (VERACYTE).

PACB Pacific Biosciences of California VCYT Veracyte WAT Waters CERS Cerus FLDM Fluidigm NEO NeoGenomics PKI PerkinElmer TTOO T2 Biosystms ANGO AngioDynamics LAB Standard Biotools

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score